Aflatoxin B1 DNA adducts in smeared tumor tissue from patients with hepatocellular carcinoma

Hepatology ◽  
1992 ◽  
Vol 16 (5) ◽  
pp. 1150-1155 ◽  
Author(s):  
Chien-Jen Chen ◽  
Yu-Jing Zhang ◽  
Sheng-Nan Lu ◽  
Regina M. Santella
Keyword(s):  
Hepatocellular Carcinoma ◽  
Dna Adducts ◽  
Aflatoxin B1 ◽  
Tumor Tissue

scholarly journals MicroRNA-24 Modulates Aflatoxin B1-Related Hepatocellular Carcinoma Prognosis and Tumorigenesis

2014 ◽  
Vol 2014 ◽  
pp. 1-13 ◽  
Author(s):  
Yi-Xiao Liu ◽  
Xi-Dai Long ◽  
Zhi-Feng Xi ◽  
Yun Ma ◽  
Xiao-Ying Huang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Dna Adducts ◽  
Aflatoxin B1 ◽  
Tissue Samples ◽  
Noncancerous Tissue ◽  
Free Survival ◽  
Tumor Tissues ◽  
Neoplastic Process ◽  
First Time

MicroRNA-24 (miR-24) may be involved in neoplastic process; however, the role of this microRNA in the hepatocellular carcinoma (HCC) related to aflatoxin B1 (AFB1) has not been well elaborated. Here, we tested miR-24 expression in 207 pathology-diagnosed HCC cases from high AFB1 exposure areas and HCC cells. We found that miR-24 was upregulated in HCC tumor tissues relative to adjacent noncancerous tissue samples, and that the high expression of miR-24 was significantly correlated with larger tumor size, higher microvessel density, and tumor dedifferentiation. Additionally, this microRNA overexpression modified the recurrence-free survival (relative hazard ratio [HR], 4.75; 95% confidence interval [CI], 2.66–8.47) and overall survival (HR=3.58, 95% CI = 2.34–5.46) of HCC patients. Furthermore, we observed some evidence of joint effects between miR-24 and AFB1 exposure on HCC prognosis. Functionally, miR-24 overexpression progressed tumor cells proliferation, inhibited cell apoptosis, and developed the formation of AFB1-DNA adducts. These results indicate for the first time that miR-24 may modify AFB1-related HCC prognosis and tumorigenesis.

Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan

2011 ◽  
Vol 31 (9) ◽  
pp. 1366-1372 ◽  
Author(s):  
Ken Shirabe ◽  
Takeo Toshima ◽  
Akinobu Taketomi ◽  
Kennichi Taguchi ◽  
Tomoharu Yoshizumi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Dna Adducts ◽  
Aflatoxin B1 ◽  
Tp53 Mutations ◽  
Southern Japan ◽  
Low Exposure

scholarly journals Repair of aflatoxin B1 DNA adducts by the UvrABC endonuclease of Escherichia coli.

1993 ◽  
Vol 268 (11) ◽  
pp. 7990-8002
Author(s):  
C.A. Oleykowski ◽  
J.A. Mayernik ◽  
S.E. Lim ◽  
J.D. Groopman ◽  
L. Grossman ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Dna Adducts ◽  
Aflatoxin B1

scholarly journals Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jian-Yao Wang ◽  
Xiang-Kun Wang ◽  
Guang-Zhi Zhu ◽  
Xin Zhou ◽  
Jun Yao ◽  
...  
Keyword(s):  
Gene Expression ◽  
Hepatocellular Carcinoma ◽  
Tumor Tissue ◽  
Bioinformatics Analysis ◽  
Mrna Level ◽  
Normal Liver ◽  
Predictive Index ◽  
Expression Levels ◽  
Interactive Analysis ◽  
Diagnostic Values

Abstract Backgroud In our current work, we aimed to investigate the expressions of glypican (GPC) family genes at the mRNA level and assess their prognostic significances in patients with hepatocellular carcinoma (HCC). Methods The pathological roles of GPC family genes were examined using bioinformatics analysis. The diagnostic values of GPC genes were explored with the Gene Expression Profiling Interactive Analysis. Moreover, the mRNA expression and prognostic values of GPC genes were assessed via the KM plotter database. Results Our data showed that the expression of GPC-3 was dramatically increased in the liver tumor tissue. Moreover, the expressions of the other five GPC family members were not significantly different between the tumor and normal liver tissues (P > 0.05). Furthermore, the up-regulation of GPC-1 at the mRNA level was dramatically correlated to the reduced overall survival (OS) for all HCC patients (hazard ratio = 2.03, 95% confidence intervals =1.44–2.87, P = 4.1e-05) compared with its low-expression group. Besides, the prognosis of the Caucasians was related to most GPC family genes, while the prognosis of the Asian race was only related to the expression of GPC-2. Besides, for pathological factors, including stage, grade, AJCC, and vascular invasion, the higher the pathological grade and vascular invasiveness, the lower the expression levels of GPC family genes (P < 0.05). Finally, the expression levels of GPC-1, 2, and 3 in the hepatitis group were related to the poor prognosis of HCC in the risk factor (alcohol consumption and hepatitis) subgroup (P < 0.05). Conclusions Our findings indicated that GPC-3 was dysregulated in HCC compared with paracancerous tissues. The expression of GPC-1 could be used as a potent predictive index for the general prognosis of HCC. The pathology, patients, and risk factors might affect the prognostic value of GPC family genes in HCC.

scholarly journals Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Stine Karlsen Oversoe ◽  
Michelle Simone Clement ◽  
Britta Weber ◽  
Henning Grønbæk ◽  
Stephen Jacques Hamilton-Dutoit ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Mutation Rate ◽  
Detection Rate ◽  
Tumor Tissue ◽  
Circulating Tumor Dna ◽  
Treatment Modalities ◽  
Advanced Hepatocellular Carcinoma ◽  
Tissue Samples ◽  
The Impact ◽  
Tumor Dna

Abstract Background and aims Studies suggest that mutations in the CTNNB1 gene are predictive of response to immunotherapy, an emerging therapy for advanced hepatocellular carcinoma (HCC). Analysis of circulating tumor DNA (ctDNA) offers the possibility of serial non-invasive mutational profiling of tumors. Combining tumor tissue and ctDNA analysis may increase the detection rate of mutations. This study aimed to evaluate the frequency of the CTNNB1 p.T41A mutation in ctDNA and tumor samples from HCC patients and to evaluate the concordance rates between plasma and tissue. We further evaluated changes in ctDNA after various HCC treatment modalities and the impact of the CTNNB1 p.T41A mutation on the clinical course of HCC. Methods We used droplet digital PCR to analyze plasma from 95 patients and the corresponding tumor samples from 37 patients during 3 years follow up. Results In tumor tissue samples, the mutation rate was 8.1% (3/37). In ctDNA from HCC patients, the CTNNB1 mutation rate was 9.5% (9/95) in the pre-treatment samples. Adding results from plasma analysis to the subgroup of patients with available tissue samples, the mutation detection rate increased to 13.5% (5/37). There was no difference in overall survival according to CTNNB1 mutational status. Serial testing of ctDNA suggested a possible clonal evolution of HCC or arising multicentric tumors with separate genetic profiles in individual patients. Conclusion Combining analysis of ctDNA and tumor tissue increased the detection rate of CTNNB1 mutation in HCC patients. A liquid biopsy approach may be useful in a tailored therapy of HCC.

GSTM1 and XRCC3 polymorphisms: Effects on levels of aflatoxin B1-DNA adducts

2009 ◽  
Vol 21 (3) ◽  
pp. 177-184 ◽  
Author(s):  
Xi-dai Long ◽  
Yun Ma ◽  
Zhou-lin Deng
Keyword(s):  
Dna Adducts ◽  
Aflatoxin B1

scholarly journals Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposure

2017 ◽  
Vol 6 (10) ◽  
pp. 2357-2369 ◽  
Author(s):  
Xiao Xiang ◽  
Hong-Gui Qin ◽  
Xue-Mei You ◽  
Yan-Yan Wang ◽  
Lu-Nan Qi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Aflatoxin B1 ◽  
Hepatitis B Virus Infection ◽  
B Virus
Sign in / Sign up

Export Citation Format

Share Document